Related Experiment Video
Updated: Jun 29, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
Prandial Insulins: A Person-Centered Choice
Bhawna Attri1, Lakshmi Nagendra2, Deep Dutta3
1Department of Endocrinology, Sarvodaya Hospital, Faridabad, Haryana, India.
Current Diabetes Reports
|April 3, 2024
Summary
Understanding prandial insulins, including rapid-acting and ultra-rapid analogs, is key to managing post-meal blood glucose spikes in diabetes. This knowledge optimizes treatment for better glycemic control and fewer complications.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Postprandial hyperglycemia significantly contributes to diabetes complications.
- Prandial insulins aim to mimic natural insulin release post-meal.
- Effective management of post-meal glucose spikes is crucial for diabetic patients.
Purpose of the Study:
- To review the diverse landscape of prandial insulin options.
- To highlight their role in optimizing glycemic management.
- To discuss clinical applications in diabetes care.
Main Methods:
- Review of current prandial insulin types: human regular, rapid-acting analogs (lispro, aspart, glulisine), ultra-rapid analogs (faster aspart, ultra-rapid lispro), and inhaled insulin.
- Analysis of pharmacokinetic profiles and delivery methods (basal-bolus, pumps).
- Examination of specific use cases, including pregnancy-related hyperglycemia.
Main Results:
- Rapid- and ultra-rapid acting analogs offer faster onset and shorter duration than human regular insulin.
- Inhaled insulin provides an alternative delivery route.
- Specific analogs are recommended for managing hyperglycemia during pregnancy.
- Prandial insulins can be integrated into various insulin regimens.
Conclusions:
- Diverse prandial insulin options allow for tailored glycemic management.
- Understanding these insulins optimizes post-meal glucose control.
- Ongoing research aims to refine prandial insulin therapy and delivery.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169
01:27Insulin Formulations: Types and Delivery
193
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
193
01:06Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
01:24Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
01:15Diabetes: Management and Pharmacotherapy
277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
01:22Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K